Scarica l'app Stockscreener
0.4555
1.04%
-0.0145
Precedente Chiudi:
$0.47
Aprire:
$0.457
Volume 24 ore:
15,548
Relative Volume:
0.04
Capitalizzazione di mercato:
$3.55M
Reddito:
$686.00K
Utile/perdita netta:
$-11.76M
Rapporto P/E:
-0.1476
EPS:
-3.0856
Flusso di cassa netto:
$-9.40M
1 W Prestazione:
+3.10%
1M Prestazione:
-23.75%
6M Prestazione:
+132.55%
1 anno Prestazione:
-66.05%
Intervallo 1D:
$0.457
$0.4651
Intervallo di 1 settimana:
$0.4264
$0.486
Portata 52W:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Nome
Azitra Inc
Settore
Industria
Telefono
203 646 6446
Indirizzo
21 Business Park Drive, Branford
Confronta AZTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| AZTR | 0.461 | 3.55M | 686.00K | -11.76M | -9.40M | -3.0856 |
| VRTX | 445.32 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.78 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 584.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.17 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Azitra Inc Borsa (AZTR) Ultime notizie
AZTR: Planning 2nd Site for ATR-12 Trial - MSN
Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia
500: Something went wrong - Investing.com Canada
Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire
Azitra to Present at BIO-Europe 2024 - BioSpace
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk
Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com
Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World
Azitra Inc’s latest rating changes from various analysts - Knox Daily
A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News
Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex
Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News
Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance
Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com
Views of Wall Street’s Leading Experts on Azitra Inc - SETE News
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex
Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily
FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com
A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News
Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily
Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Understanding AZTR stock ratios for better investment decisions - US Post News
Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex
Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra Inc Azioni (AZTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Capitalizzazione:
|
Volume (24 ore):